In that trial, the Sanofi drug candidate slowed disability progression when compared with a placebo, an ineffective dummy drug. "Tolebrutinib represents an unprecedented breakthrough as a ...
A pill Novo acquired produced modest weight loss but raised safety questions. Elsewhere, Sanofi detailed the silver lining it found in a recent study and a heart drug developer’s shares surged.
Some results have been hidden because they may be inaccessible to you